SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$9.8b

SciClone Pharmaceuticals (Holdings) Management

Management criteria checks 3/4

SciClone Pharmaceuticals (Holdings)'s CEO is Hong Zhao, appointed in Jun 2020, has a tenure of 3.75 years. total yearly compensation is CN¥17.03M, comprised of 45% salary and 55% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth HK$8.02M. The average tenure of the management team and the board of directors is 2.6 years and 3.1 years respectively.

Key information

Hong Zhao

Chief executive officer

CN¥17.0m

Total compensation

CEO salary percentage45.0%
CEO tenure3.8yrs
CEO ownership0.08%
Management average tenure2.6yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

CEO Compensation Analysis

How has Hong Zhao's remuneration changed compared to SciClone Pharmaceuticals (Holdings)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

CN¥953m

Mar 31 2023n/an/a

CN¥904m

Dec 31 2022CN¥17mCN¥8m

CN¥855m

Sep 30 2022n/an/a

CN¥844m

Jun 30 2022n/an/a

CN¥833m

Mar 31 2022n/an/a

CN¥878m

Dec 31 2021CN¥26mCN¥7m

CN¥923m

Sep 30 2021n/an/a

CN¥837m

Jun 30 2021n/an/a

CN¥779m

Mar 31 2021n/an/a

CN¥766m

Dec 31 2020CN¥29mCN¥7m

CN¥754m

Sep 30 2020n/an/a

CN¥817m

Dec 31 2019CN¥15mCN¥6m

CN¥615m

Compensation vs Market: Hong's total compensation ($USD2.36M) is above average for companies of similar size in the Hong Kong market ($USD569.28K).

Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.


CEO

Hong Zhao (60 yo)

3.8yrs

Tenure

CN¥17,030,000

Compensation

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...


Leadership Team

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director3.8yrsCN¥17.03m0.082%
CN¥ 8.0m
Rongrong Pan
Joint Company Secretary3.1yrsno data0.58%
CN¥ 56.4m
Chihwen Shao
VP & Head of Technical Operations and Pharmacovigilance2.2yrsno datano data
Min Jia
VP & Head of Immunization Business Unitno datano datano data
Yansong Chang
VP & GM of Oncology Business Unitno datano datano data
Mingxiang Wu
VP and Head of Market Access & Commercial Operation (MACO) Departmentno datano datano data
Xiaoning Guo
VP, Head of Research & Development Department and Chief Medical Officerno datano datano data
Lianzong Wu
VP and Head of Registration & Pharmaceutical Affairs Departmentno datano datano data
Li Mao
VP, GM of Research and Development & Chief Medical Officer1.8yrsno datano data
Min Wu
VP & Chief Business Development Officerless than a yearno datano data
Sin Man Chan
Joint Company Secretary3.1yrsno datano data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Management: 6600's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director3.8yrsCN¥17.03m0.082%
CN¥ 8.0m
Rongrong Pan
Joint Company Secretaryless than a yearno data0.58%
CN¥ 56.4m
Guoen Liu
Independent Non-Executive Director3.1yrsCN¥658.00kno data
Zhenfu Li
Non-Executive Chairman3.8yrsno datano data
Wendy Hayes
Independent Non-Executive Director3.1yrsCN¥658.00kno data
Haixia Wang
Non-Executive Director2.8yrsno datano data
Daniel Luzius Vasella
Non-Executive Director3.6yrsCN¥658.00kno data
Yi-Hsien Lin
Non-Executive Director3.1yrsno datano data
Ping Chen
Independent Non-Executive Director3.1yrsCN¥658.00kno data
Yushao Gu
Independent Non-Executive Director3.1yrsCN¥658.00kno data

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: 6600's board of directors are considered experienced (3.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.